These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 2938955

  • 1. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
    Bonte J, Janssens JP, Ide P.
    Eur J Gynaecol Oncol; 1986; 7(1):45-50. PubMed ID: 2938955
    [Abstract] [Full Text] [Related]

  • 2. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
    Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H.
    Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
    [Abstract] [Full Text] [Related]

  • 3. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
    Noguchi S, Yamamoto H, Inaji H, Imaoka S, Koyama H.
    Jpn J Cancer Res; 1989 Mar; 80(3):244-8. PubMed ID: 2524460
    [Abstract] [Full Text] [Related]

  • 4. New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.
    Vanderstappen D, Bonte J.
    Eur J Gynaecol Oncol; 1992 Mar; 13(2):113-23. PubMed ID: 1534051
    [Abstract] [Full Text] [Related]

  • 5. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
    Thurzó L.
    Zentralbl Gynakol; 1990 Mar; 112(17):1111-5. PubMed ID: 2148245
    [Abstract] [Full Text] [Related]

  • 6. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study.
    De Lena M, Tommasi S, Schittulli F, Lorusso V, Paradiso A.
    Tumori; 1990 Apr 30; 76(2):190-5. PubMed ID: 2139523
    [Abstract] [Full Text] [Related]

  • 7. Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a-anthracene-induced rat mammary tumors in relation to hormone receptors.
    Tominaga T, Yoshida Y, Kitamura M, Kosaki G.
    Jpn J Cancer Res; 1985 Nov 30; 76(11):1120-5. PubMed ID: 2935517
    [Abstract] [Full Text] [Related]

  • 8. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N, Salzer H, Sevelda P, Breitenecker G, Czerwenka K, Kucera H.
    Gynakol Rundsch; 1990 Nov 30; 30(3):133-43. PubMed ID: 2147161
    [Abstract] [Full Text] [Related]

  • 9. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
    Kline RC, Freedman RS, Jones LA, Atkinson EN.
    Cancer Treat Rep; 1987 Mar 30; 71(3):327-8. PubMed ID: 2949831
    [No Abstract] [Full Text] [Related]

  • 10. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L, Durand M, Bonichon F, Chauvergne J.
    Bull Cancer; 1986 Mar 30; 73(2):148-54. PubMed ID: 2942203
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Hormones in gynecologic oncology].
    Maass H.
    Arch Gynecol Obstet; 1989 Mar 30; 245(1-4):466-73. PubMed ID: 2802734
    [No Abstract] [Full Text] [Related]

  • 14. The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers.
    Bonte J.
    Eur J Obstet Gynecol Reprod Biol; 1984 Dec 30; 18(5-6):335-41. PubMed ID: 6526120
    [Abstract] [Full Text] [Related]

  • 15. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S, Yamamoto H, Inaii H, Koyama H.
    Gan To Kagaku Ryoho; 1989 Nov 30; 16(11):3555-8. PubMed ID: 2530936
    [Abstract] [Full Text] [Related]

  • 16. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.
    J Clin Oncol; 2007 Oct 20; 25(30):4772-8. PubMed ID: 17876012
    [Abstract] [Full Text] [Related]

  • 17. Effects of tamoxifen, estradiol benzoate and medroxyprogesterone acetate on the growth of DMBA-induced rat mammary carcinoma.
    Zanardi S, De Menech R, Pino G, Guarneri D, Dandolo G, Sanguineti M, Moro MG, Barbi GP, Paganuzzi M, Boccardo F.
    Chemioterapia; 1985 Jun 20; 4(3):239-42. PubMed ID: 3161642
    [Abstract] [Full Text] [Related]

  • 18. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y, Tashiro H, Hisamatsu K, Shinozuka K.
    Anticancer Res; 1988 Jun 20; 8(4):647-51. PubMed ID: 2972248
    [Abstract] [Full Text] [Related]

  • 19. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
    Wada T, Matunami N, Houjou T, Morikawa E, Mori N, Nakano K, Aizawa M, Kurooka K, Kadota K, Yamato M.
    Gan To Kagaku Ryoho; 1989 May 20; 16(5):2087-92. PubMed ID: 2525004
    [Abstract] [Full Text] [Related]

  • 20. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E, Jouve M, Palangie T, Bretaudeau B, Asselain B, Magdelenat H, Merle S, Zajdela A, Pouillart P.
    Bull Cancer; 1984 May 20; 71(1):22-9. PubMed ID: 6324934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.